CA
NZ
UK
AU
IND
US
…
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
CollPlant Biotechnologies Ltd develops recombinant human collagen via a plant-based platform for regenerative-medicine, aesthetic and wound-care applications. Growth drivers include licensing and supply agreements, uptake of collagen-based implants and scaling manufacturing to address multiple therapeutic markets. The platform-led exposure to tissue engineering may appeal to investors seeking diversified biomaterials exposure.
Key risks are early-stage commercialization with a history of losses and potential financing needs, regulatory and clinical uncertainty, manufacturing scale-up challenges and competition from established collagen suppliers and alternative biomaterials.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -11.49M | -16.61M | -7.02M | -16.93M | 0.24M |
| Net income | -11.49M | -16.61M | -7.02M | -16.75M | 0.41M |
| Selling general administrative | 4.83M | 5.63M | 6.55M | 6.74M | 5.94M |
| Gross profit | 0.62M | -2.15M | 7.87M | -0.10M | 13.64M |
| Reconciled depreciation | 0.91M | 1.04M | 1.11M | 1.08M | 0.77M |
| Ebit | -11.48M | -16.59M | -7.01M | -17.10M | 0.07M |
| Ebitda | -10.57M | -15.55M | -5.91M | -16.02M | 0.85M |
| Depreciation and amortization | 0.91M | 1.04M | 1.10M | 1.08M | 0.78M |
| Operating income | -11.48M | -17.25M | -7.51M | -17.10M | 0.07M |
| Other operating expenses | 13.85M | 17.77M | 18.47M | 17.40M | 15.58M |
| Interest expense | 0.01M | 0.02M | 0.01M | 0.17M | 0.18M |
| Interest income | 0.38M | 0.74M | 0.79M | 0.32M | 0.22M |
| Net interest income | 0.36M | 0.72M | 0.50M | 0.17M | 0.18M |
| Income tax expense | - | - | -0.00M | -0.17M | -0.17M |
| Total revenue | 2.37M | 0.52M | 10.96M | 0.30M | 15.64M |
| Total operating expenses | 12.11M | 15.10M | 15.38M | 17.00M | 13.57M |
| Cost of revenue | 1.75M | 2.66M | 3.09M | 0.40M | 2.00M |
| Total other income expense net | -0.01M | 0.64M | 0.49M | 0.17M | 0.17M |
| Net income from continuing ops | -11.49M | -16.61M | -6.73M | -16.93M | 0.24M |
| Net income applicable to common shares | - | - | - | -16.93M | 0.24M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 10.79M | 18.71M | 34.13M | 37.77M | 51.22M |
| Intangible assets | 0.07M | 0.13M | 0.19M | - | - |
| Other current assets | 0.22M | 0.25M | 0.39M | 0.02M | 0.01M |
| Total liab | 4.70M | 5.25M | 5.79M | 5.49M | 6.10M |
| Total stockholder equity | 6.08M | 13.46M | 28.34M | 32.28M | 45.12M |
| Other current liab | 1.25M | 1.29M | 1.65M | 1.44M | 1.43M |
| Common stock | 5.49M | 4.98M | 4.98M | 4.87M | 4.66M |
| Capital stock | 5.49M | 4.98M | 4.98M | 4.87M | 4.66M |
| Retained earnings | -124.84M | -113.35M | -96.74M | -89.72M | -72.80M |
| Other assets | - | - | 0.00M | - | 0.21M |
| Cash | 5.95M | 11.91M | 26.91M | 29.65M | 13.15M |
| Total current liabilities | 2.67M | 2.97M | 3.25M | 3.10M | 3.01M |
| Current deferred revenue | - | - | - | - | 0.03M |
| Net debt | -3.10M | -8.83M | -23.76M | -26.74M | -9.54M |
| Short term debt | 0.81M | 0.81M | 0.62M | 0.53M | 0.52M |
| Short long term debt total | 2.85M | 3.08M | 3.16M | 2.91M | 3.61M |
| Other stockholder equity | 126.40M | 122.80M | 121.07M | 118.10M | 114.22M |
| Property plant equipment | - | - | - | - | 5.68M |
| Total current assets | 6.75M | 13.18M | 28.02M | 31.66M | 45.09M |
| Net tangible assets | - | - | - | - | 44.88M |
| Short term investments | - | - | - | 0.00M | 30.15M |
| Net receivables | 0.00M | 0.58M | 0.39M | 0.55M | 0.69M |
| Inventory | 0.57M | 0.44M | 0.71M | 1.43M | 1.08M |
| Accounts payable | 0.61M | 0.87M | 0.98M | 1.13M | 1.03M |
| Accumulated other comprehensive income | -0.97M | -0.97M | -0.97M | -0.97M | -0.97M |
| Non currrent assets other | 0.08M | 0.12M | 0.06M | 0.19M | 0.21M |
| Non current assets total | 4.04M | 5.53M | 6.10M | 6.11M | 6.14M |
| Capital lease obligations | 2.85M | 3.08M | 3.16M | 2.91M | 3.61M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.54M | -1.09M | 28.92M | -30.00M |
| Change to liabilities | - | - | - | -0.03M | 0.06M |
| Total cashflows from investing activities | -0.03M | -0.54M | -1.16M | - | -31.56M |
| Total cash from financing activities | 3.10M | 0.01M | 1.11M | 1.87M | 38.76M |
| Change to operating activities | - | - | - | - | -0.59M |
| Net income | -11.49M | -16.61M | -7.02M | -16.93M | 0.24M |
| Change in cash | -6.21M | -14.77M | -3.19M | 16.49M | 9.85M |
| Begin period cash flow | 12.16M | 26.67M | 29.86M | 13.37M | 3.53M |
| End period cash flow | 5.95M | 11.91M | 26.67M | 29.86M | 13.37M |
| Total cash from operating activities | -9.42M | -14.09M | -2.76M | -13.70M | 2.50M |
| Issuance of capital stock | 3.10M | 0.00M | 0.00M | 0.00M | 32.74M |
| Depreciation | 0.91M | 1.04M | 1.10M | 1.08M | 0.77M |
| Other cashflows from investing activities | - | -0.06M | -0.20M | - | - |
| Change to inventory | -0.13M | 0.28M | 0.75M | -0.31M | 0.18M |
| Change to account receivables | 0.36M | -0.15M | 0.01M | 0.26M | 0.56M |
| Other cashflows from financing activities | - | 0.01M | 1.11M | 1.87M | 6.02M |
| Change to netincome | - | - | - | 2.69M | 1.27M |
| Capital expenditures | 0.03M | 0.48M | 0.95M | 1.32M | 1.59M |
| Change in working capital | 0.25M | -0.26M | 1.00M | -0.54M | 0.22M |
| Stock based compensation | 1.00M | 1.72M | 1.94M | 2.17M | 1.60M |
| Other non cash items | 0.90M | 0.02M | 0.22M | 0.52M | -0.03M |
| Free cash flow | -9.45M | -14.58M | -3.72M | -15.01M | 0.91M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLGN Collplant Biotechnologies Ltd |
-0.27 6.02% |
4.13 | - | 80.00 | 2.33 | 0.88 | 1.10 | -5.97 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
| Name | Title | Year Born |
|---|---|---|
| Mr. Yehiel Tal | CEO & Director | 1952 |
| Mr. Eran Rotem CPA | Deputy CEO & CFO | 1968 |
| Dr. Ilana Belzer | Chief Operations Officer | 1960 |
| Prof. Oded Shoseyov | Founder & Chief Scientist | 1956 |
| Ms. Michal Roytman | VP of Sales & Marketing | 1985 |
| Ms. Hadas Dreiher Horowitz | VP of HR | 1977 |
| Mr. Eran Rotem C.P.A. | Deputy CEO & CFO | 1968 |
| Mr. Oren Fahimipoor | Vice President of Operations | 1982 |
| Dr. Elana Gazal | Vice President of Research & Development | 1975 |
| Ms. Hadas Dreiher Horowitz | Vice President of Human Resources | 1977 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...